JFR vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JFR exhibits a stable but fragile financial health profile with a Piotroski F-Score of 4/9 and no Altman Z-Score available. While the fund trades at a discount to book value (P/B 0.87) and below its Graham Number ($8.07), these value metrics are overshadowed by a catastrophic collapse in earnings growth (-52.80% YoY). Most critically, the dividend payout ratio of 300% indicates that the 12.56% yield is unsustainable and likely being funded by return of capital rather than earnings. Combined with a 0/100 technical trend and bearish insider activity, the outlook is negative.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
JFR vs JPM: Head-to-Head Comparison
This page compares Nuveen Floating Rate Income Fund (JFR) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.